Research Confirms MGUS Is Linked To Myeloma, But May Not Be Linked To As Many Diseases As Previously Thought – According to a study published in the August 2009 issue of Mayo Clinic Proceedings, monoclonal gammopathy of undetermined significance (MGUS) may not be linked to as many serious diseases as previously thought. MGUS is a symptomless blood disorder that is a precursor of multiple myeloma. This study confirmed a link between MGUS and 14 diseases.  However, before this study, it was also thought to be a precursor for many more diseases. These Mayo Clinic findings may save patients from unnecessary tests and treatment. For more information, please see the Mayo Clinic press release.

Lawsuit Claims Celgene Corporation Misappropriated The Idea Behind Thalidomide – On August 24, Beth R. Jacobson filed a lawsuit against Celgene Corporation claiming “misappropriation of an idea” and “unjust enrichment” concerning the company’s sale of thalidomide (Thalomid) and Revlimid (lenalidomide) for the treatment of myeloma. The suit claims that Jacobson developed the original idea for treating myeloma with thalidomide and is consequently entitled to compensation based on established legal precedent. Jacobson seeks a minimum of $300 million in past damages and 25 percent of the future profits from the sale of Celgene’s thalidomide products. For more information, please see Ms. Jacobson's press release.

Light The Night Walks – On September 11, the Leukemia & Lymphoma Society (LLS) will hold Light the Night Walks in St. Louis and St. Peters, MO. Participants will walk along a two- or three-mile route, carrying a lighted balloon, in support of those touched by blood cancer. For more information, please visit the LLS Web sites for each of the events.

For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.